Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

CASI Pharmaceuticals (CASI) Other Operating Expenses (2022 - 2025)

Historic Other Operating Expenses for Pharmaceuticals (CASI) over the last 4 years, with Q2 2025 value amounting to -$5.4 million.

  • Pharmaceuticals' Other Operating Expenses fell 4685.79% to -$5.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$13.4 million, marking a year-over-year increase of 4901.83%. This contributed to the annual value of $479000.0 for FY2024, which is 10484.62% up from last year.
  • As of Q2 2025, Pharmaceuticals' Other Operating Expenses stood at -$5.4 million, which was down 4685.79% from -$4.4 million recorded in Q1 2025.
  • In the past 5 years, Pharmaceuticals' Other Operating Expenses ranged from a high of $4.9 million in Q2 2023 and a low of -$29.8 million during Q4 2022
  • For the 4-year period, Pharmaceuticals' Other Operating Expenses averaged around -$4.1 million, with its median value being -$808500.0 (2022).
  • In the last 5 years, Pharmaceuticals' Other Operating Expenses skyrocketed by 13808.13% in 2023 and then plummeted by 20174.22% in 2024.
  • Quarter analysis of 4 years shows Pharmaceuticals' Other Operating Expenses stood at -$29.8 million in 2022, then rose by 29.44% to -$21.0 million in 2023, then soared by 82.58% to -$3.7 million in 2024, then plummeted by 46.86% to -$5.4 million in 2025.
  • Its Other Operating Expenses stands at -$5.4 million for Q2 2025, versus -$4.4 million for Q1 2025 and -$3.7 million for Q2 2024.